Treatment of menstrual cycle-induced symptoms
Patent Information
- Application Number
- IL290880
- Authority / Receiving Office
- IL · IL
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-08-26
- Filing Date
- 2020-08-26
- Publication Date
- 2026-07-01
- Estimated Expiration
- 2040-08-26
AI Technical Summary
Current treatments for menstrual cycle-induced symptoms, such as PMS and PMDD, are often costly and have significant side effects, and existing pharmacological solutions are not ideal for addressing the full spectrum of physical and behavioral symptoms effectively.
The use of 3-methylmethcathinone (3-MMC) is proposed for treating menstrual cycle-induced symptoms, administered in specific dosages and timing relative to the menstrual cycle to alleviate both somatic and mood-related symptoms, with a kit including the drug and instructions for administration.
3-MMC provides effective relief for a range of menstrual cycle-induced symptoms with minimal side effects, improving quality of life by reducing symptom severity and duration, and can be administered before, during, or after symptoms occur, offering a more effective alternative to conventional treatments.